Equities research analysts at Bank of America started coverage on shares of Henry Schein (NASDAQ:HSIC) in a report released on Tuesday, Marketbeat reports. The firm set a “neutral” rating and a $76.00 price target on the stock. Bank of America’s target price points to a potential upside of 14.82% from the company’s current price.
A number of other equities analysts have also recently issued reports on HSIC. Barrington Research reiterated an “outperform” rating on shares of Henry Schein in a report on Wednesday, February 21st. Leerink Swann set a $75.00 target price on Henry Schein and gave the stock a “hold” rating in a report on Wednesday, February 21st. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $77.00 target price (down previously from $79.00) on shares of Henry Schein in a report on Thursday, February 15th. Stephens began coverage on Henry Schein in a report on Tuesday, November 28th. They set an “equal weight” rating and a $76.00 target price for the company. Finally, TheStreet cut Henry Schein from a “b” rating to a “c+” rating in a report on Monday, November 6th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $83.07.
Henry Schein (NASDAQ:HSIC) opened at $66.19 on Tuesday. The stock has a market capitalization of $10,329.79, a PE ratio of 18.69, a price-to-earnings-growth ratio of 1.65 and a beta of 1.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.76 and a current ratio of 1.45. Henry Schein has a 1-year low of $63.01 and a 1-year high of $93.50.
In other news, Director Barry J. Alperin sold 5,796 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $70.76, for a total value of $410,124.96. Following the completion of the transaction, the director now owns 48,172 shares in the company, valued at approximately $3,408,650.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.19% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. FTB Advisors Inc. lifted its stake in Henry Schein by 100.0% in the 3rd quarter. FTB Advisors Inc. now owns 1,484 shares of the company’s stock valued at $120,000 after purchasing an additional 742 shares during the last quarter. Captrust Financial Advisors acquired a new stake in Henry Schein in the 4th quarter valued at about $141,000. Lee Financial Co lifted its stake in Henry Schein by 100.0% in the 3rd quarter. Lee Financial Co now owns 1,756 shares of the company’s stock valued at $144,000 after purchasing an additional 878 shares during the last quarter. Advisory Services Network LLC lifted its stake in Henry Schein by 430.1% in the 4th quarter. Advisory Services Network LLC now owns 2,099 shares of the company’s stock valued at $147,000 after purchasing an additional 1,703 shares during the last quarter. Finally, Westside Investment Management Inc. lifted its stake in Henry Schein by 100.0% in the 3rd quarter. Westside Investment Management Inc. now owns 2,000 shares of the company’s stock valued at $160,000 after purchasing an additional 1,000 shares during the last quarter. Institutional investors own 88.58% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3229976/henry-schein-hsic-now-covered-by-analysts-at-bank-of-america.html.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.